-- 
Lundbeck Buys $16 Million Stake in Proximagen to Develop Drugs

-- B y   F r a n c e s   S c h w a r t z k o p f f
-- 
2011-09-29T06:53:40Z

-- http://www.bloomberg.com/news/2011-09-29/lundbeck-buys-16-million-stake-in-proximagen-to-develop-drugs.html
H. Lundbeck A/S, Denmarkâ€™s second-
largest drugmaker, agreed to make a 10.3 million-pound ($16
million) investment in  Proximagen Group plc (PRX)  as part of a
strategic partnership agreement to develop drugs for epilepsy,
pain and inflammatory disorders.  Under the agreement, London-based Proximagen will issue 5.7
million new shares to Lundbeck at a price of 180 pence a share,
according to a statement distributed by Proximagen.  To contact the editor responsible for this story:
Frances Schwartzkopff at 
 fschwartzko1@bloomberg.net  